Look to Worldwide to Guide Your Macular Degeneration Treatment Study

Age-related macular degeneration is the leading cause of vision loss in the United States. It’s an incurable condition that can make it impossible for people to read or drive and, as people from the baby-boom generation move deeper into their golden years, it’s a condition that threatens to reach epidemic proportions. The National Eye Institute indicates that the incidence of macular degeneration grew by more than 18% in the decade between 2000 and 2010. It also projects that by 2030 there will be well over 3 million cases of macular degeneration in America – and more than 5.4 million by 2050.[1]

Are you working on a breakthrough therapy that could prevent or repair that damage wrought by macular degeneration? There are millions of people eager to benefit, but before you can bring it to market you need to traverse a series of clinical trials to prove the safety and efficacy of your treatment.

Worldwide Clinical Trials can help you succeed in that endeavor. With more than 30 years of experience, Worldwide is an internationally acclaimed expert in clinical trial management. We offer full-service support for Phase I-Phase IV clinical trials, as well as real-world evidence studies that can help you understand the effects of your work over both the short and long term.

Researchers partnering with Worldwide know that they’ll be working with an award-winning, stable team of project professionals who already have experience in research related to sensory disorders. They know they can rely on Worldwide for insightful feedback on development plans, for detailed and expert feasibility analyses, and for the resources and management skills to bring a trial to completion on time and on budget.

[1] https://nei.nih.gov/eyedata/amd